The liver and lovastatin (Q34683472)

3 August 2017

1 reference

title

The liver and lovastatin (English)

1 reference

3 August 2017

Keith G Tolman

1

1 reference

PubMed ID

12062731

3 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

American Journal of Cardiology

3 August 2017

1 reference

3 August 2017

89

1 reference

3 August 2017

1374-1380

1 reference

3 August 2017

12

1 reference

Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

Preclinical evaluation of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

Effect on Hepatic Morphology of Treatment of Obesity by Fasting, Reducing Diets and Small-Bowel Bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

Outpatient Drug-Induced Parenchymal Liver Disease Requiring Hospitalization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

Jaundice after repeated exposure to halothane: an analysis of Reports to the Committee on Safety of Medicines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902355-X

10.1016/S0002-9149(02)02355-X

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

12062731